Drug Profile
Research programme: infectious disease vaccines - Themis Bioscience
Alternative Names: Cytomegalovirus vaccine - Themis Bioscience; Dengue vaccine - Themis Bioscience; MERS vaccine - Themis Bioscience; Norovirus vaccine - Themis Bioscience; Respiratory syncytial vaccine - Themis Bioscience; Yellow fever vaccine - Themis BioscienceLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Themis Bioscience
- Developer Institut Pasteur; Themis Bioscience
- Class Attenuated vaccines; Cytomegalovirus vaccines; Dengue vaccines; Respiratory syncytial virus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cytomegalovirus infections; Dengue; Middle East respiratory syndrome coronavirus; Norovirus infections; Respiratory syncytial virus infections; Yellow fever
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Cytomegalovirus infections (Prevention) in Austria (Parenteral)
- 25 Apr 2023 Discontinued - Preclinical for Dengue in Austria (Parenteral)
- 25 Apr 2023 Discontinued - Preclinical for Middle East respiratory syndrome coronavirus (Prevention) in Austria (Parenteral)